Receptors for hormones and growth factors and (ONCO)‐gene amplification in human ovarian cancer

International Journal of Cancer

Volumn 52, Issue 2, 1992, Pages 218-224

  Berns, Els M J J ^a   Klijn, Jan G M ^a   Henzen‐Logmans, Sonja C ^a   Rodenburg, Cees J ^a   van der Burg, Maria E L ^a   Foekens, John A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; GROWTH FACTOR RECEPTOR; HORMONE RECEPTOR; SOMATOMEDIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL;

ADENOCARCINOMA; AUTORADIOGRAPHY; CYTOSOL; FEMALE; GENE AMPLIFICATION; GENES, MYC; HUMAN; OVARIAN NEOPLASMS; OVARY; PROTO-ONCOGENES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CELL SURFACE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, SOMATOMEDIN; SUPPORT, NON-U.S. GOV'T;

EID: 0026786085     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.2910520211     Document Type: Article

References (27)

1. Epidermal growth factor receptor expression in gynaecological malignancies
2. Clinical significance of oncogenes and growth factors in ovarian carcinomas
3. MILLER. c‐Myc amplification in ovarian cancer
4. Hydroxylapatite assay to measure epidermal growth factor receptor in human primary breast tumors
5. Overexpression of HER2/Neu is associated with poor survival in advanced epithelial ovarian cancer
6. EGF‐R expression in normal ovarian epithelium and ovarian cancer. 1. Correlation of receptor expression with prognostic factors in patients with ovarian cancer
7. Prevalence of amplification of the oncogenes c‐Myc, HER2/Neu, and int‐2 in a thousand human breast tumours: correlation with steroid receptor
8. Revision of the standards for the assessment of hormone receptors in human breast cancer
9. Cell biological prognostic factors in breast cancer: a review
10. Prognostic value of receptors for insulin‐Like growth factor‐1, somalostatin, and epidermal growth factor in human breast cancer
11. Prognostic value of pS2 protein and receptors for epidermal growth factor (eGF‐R), insulin‐Like growth factor‐1 (iGF‐L‐R), and somatostatin (sS‐R) in patients with breast and ovarian cancer
12. Six methods for direct radioiodination of mouse epidermal growth factor compared: effect of nonequivalence in binding behaviour between labeled and unlabeled ligand
13. The clinical significance of epidermal growth factor receptor (eGF‐R) in human breast cancer: a review on 5,232 patients
14. The neu(c‐ErbB‐2) oncogene
15. Receptors for epidermal growth factor and insulin‐Like growth factor 1 and their relation to steroid receptors in human breast cancer
16. Insulin‐Like growth factor‐1 receptors in human breast cancer and their relation to estradiol and progesterone receptors
17. Endocrine factors in common epithelial ovarian cancer
18. EGF receptors in human breast cancer on viable and necrotic tumour cells
19. Epidermal‐Growth‐Factor receptor status as predictor of early recurrence of and death from breast cancer
20. Cathepsin D assay in ovarian cancer: correlation with pathological features and receptors for oestrogen, progesterone and epidermal growth factor
21. Human breast cancer: correlation of relapse and survival with amplification of the HER2/Neu oncogene
22. Studies of the HER2/Neu proto‐Oncogene in human breast and ovarian cancer
23. Determination of cellular oncogene rearrangement or amplification in ovarian adenocarcinomas
24. Detection of pS2 messenger RNA in aynecological cancers
25. Amplification and rearrangement of c‐ErbB protooncogenes in carcinoma of human female genital tract
26. Distinction of low grade from high grade human ovarian carcinomas on the basis of losses of heterozygosity on chromosomes 3, 6, and 11 and HER‐2/Neu gene amplification
27. A unique pattern of proto‐Oncogene abnormalities in ovarian adenocarcinomas